ReviewDrug design, development and therapy2015
Bacteriophage-based therapy in cystic fibrosis-associated Pseudomonas aeruginosa infections: rationale and current status.
Review in Drug design, development and therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 77 citations in OpenAlex.
- Mechanisms ofMedicina (Kaunas, Lithuania) · 2026Review
- Bacteriophage Therapy in Cystic Fibrosis: Emerging Strategies for Managing ChronicDrug design, development and therapy · 2026Review
- Review
- Bacteriophage Therapy on an In Vitro Wound Model and Synergistic Effects in Combination with Beta-Lactam Antibiotics.Antibiotics (Basel, Switzerland) · 2024Article
- A Novel Bacteriophage Infecting Multi-Drug- and Extended-Drug-ResistantAntibiotics (Basel, Switzerland) · 2024Article
- Post-Burn and Surgical Scar Reconstruction with Tissue Expanders: Review of the Literature and Our Local Experience.Reports (MDPI) · 2023Article
- Current knowledge in the use of bacteriophages to combat infections caused by Pseudomonas aeruginosa in cystic fibrosis.Folia microbiologica · 2023Review
- Insights into Personalised Medicine in Bronchiectasis.Journal of personalized medicine · 2023Review
- Chemical-Biology and Metabolomics Studies in Phage-Host Interactions.Advances in experimental medicine and biology · 2023Article
- Antibacterial efficacy of lytic phages against multidrug-resistant Pseudomonas aeruginosa infections in bacteraemia mice models.BMC microbiology · 2022Article
- Novel Bacteriophages Show Activity against Selected Australian Clinical Strains ofMicroorganisms · 2022Article
- An updated gene regulatory network reconstruction of multidrug-resistant Pseudomonas aeruginosa CCBH4851.Memorias do Instituto Oswaldo Cruz · 2022Article
- Preclinical Development of a Bacteriophage Cocktail for Treating Multidrug ResistantMicroorganisms · 2021Article
- Current and Emerging Therapies to Combat Cystic Fibrosis Lung Infections.Microorganisms · 2021Review
- Successful Intratracheal Treatment of Phage and Antibiotic Combination Therapy of a Multi-Drug ResistantAntibiotics (Basel, Switzerland) · 2021Article
- The Potential Role of Bacteriophages in the Treatment of Recalcitrant Chronic Rhinosinusitis.Antibiotics (Basel, Switzerland) · 2021Review
- Advances in Bacteriophage Therapy against Relevant MultiDrug-Resistant Pathogens.Antibiotics (Basel, Switzerland) · 2021Review
- Rekindling of a Masterful Precedent; Bacteriophage: Reappraisal and Future Pursuits.Frontiers in cellular and infection microbiology · 2021Review
- Bacteriophage therapy against Pseudomonas aeruginosa biofilms: a review.Annals of clinical microbiology and antimicrobials · 2020Review
- Pf Bacteriophage and Their Impact on Pseudomonas Virulence, Mammalian Immunity, and Chronic Infections.Frontiers in immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary infections involving Pseudomonas aeruginosa are among the leading causes of the deterioration of the respiratory status of cystic fibrosis (CF) patients. The emergence of multidrug-resistant strains in such populations, favored by iterative antibiotic cures, has led to the urgent need for new therapies. Among them, bacteriophage-based therapies deserve a focus. One century of empiric use in the ex-USSR countries suggests that bacteriophages may have beneficial effects against a large range of bacterial infections. Interest in bacteriophages has recently renewed in Western countries, and the in vitro data available suggest that bacteriophage-based therapy may be of significant interest for the treatment of pulmonary infections in CF patients. Although the clinical data concerning this specific population are relatively scarce, the beginning of the first large randomized study evaluating bacteriophage-based therapy in burn infections suggests that the time has come to assess the effectiveness of this new therapy in CF P. aeruginosa pneumonia. Consequently, the aim of this review is, after a brief history, to summarize the evidence concerning bacteriophage efficacy against P. aeruginosa and, more specifically, the in vitro studies, animal models, and clinical trials targeting CF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.